Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BG-75098

Small molecule · Degrader of cyclin-dependent kinase 2 (CDK2) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer
1 Registered trials

What is BG-75098?

BG-75098 is an orally bioavailable chimeric degradation activation compound that binds CDK2 and an E3 ubiquitin ligase, driving ubiquitination and proteasomal degradation of CDK2. By reducing CDK2 activity, it inhibits Rb phosphorylation and blocks the G1/S transition. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
cyclin-dependent kinase 2 (CDK2), cyclin E1 (CCNE1) (binding partner it blocks), retinoblastoma protein (RB1) (binding partner it blocks)
Mechanism
Degrader of cyclin-dependent kinase 2 (CDK2)
Pathways
ubiquitin-proteasome degradation, Rb phosphorylation, G1/S cell cycle transition, apoptosis
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07226349 Phase 1 Advanced Solid Tumor Recruiting ONC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on CDK2

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BG-75098

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.